Research programme: PPAR delta agonists - Cerenis/Nippon Chemiphar

Drug Profile

Research programme: PPAR delta agonists - Cerenis/Nippon Chemiphar

Alternative Names: NP-016; NP-022; PPARδ agonists - Cerenis/Nippon Chemiphar

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Chemiphar
  • Developer Cerenis Therapeutics; Nippon Chemiphar
  • Class Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Low HDL cholesterol

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Low-HDL-cholesterol in France (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Low-HDL-cholesterol in Japan (PO)
  • 04 Sep 2008 Pharmacokinetics and pharmacodynamics data from a preclinical trials in Low HDL cholesterol presented at the 20th International Symposium on Medicinal Chemistry (ISMC-20008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top